Jump to content

Anil Mishra

From Wikipedia, the free encyclopedia

Anil Mishra is an Indian doctor, scientist and professor of Medicine.[1] He directs the Eosinophilic Disorder Centre at Tulane School of Medicine.[2][3]

Early life and education

[edit]

Mishra had his BSc and PhD from Maharaja College, Jaipur and Kanpur University, India respectively.[4] His researches were focused on Indian environmental pollution and its impact to human health especially the Bhopal disaster.[5]

Career

[edit]

Mishra has contributed to the field of pulmonary diseases and eosinophilic disorders,[6] role of eosinophils in allergic and gastrointestinal diseases.[7]


Awards

[edit]

Mishra is an elected fellow of the American Academy of Allergy, Asthma & Immunology (FAAAAI) and the American Gastroenterological Association (AGA).[8]

Publications

[edit]

References

[edit]
  1. ^ "Anil Mishra, PhD | Tulane School of Medicine". medicine.tulane.edu. Retrieved 2024-04-02.
  2. ^ Mishra, Anil; Dwivedi, Premendra D.; Verma, Ashish S.; Mishra, Jaya; Sinha, M.; Dutta, K. K.; Ray, P. K. (1991-11-01). "Modulation of microsomal membrane-associated detoxication enzymes activity by methyl isocyanate (MIC) exposure". Bulletin of Environmental Contamination and Toxicology. 47 (5): 675–681. Bibcode:1991BuECT..47..675M. doi:10.1007/BF01701133. ISSN 1432-0800. PMID 1813080.
  3. ^ "usnews.com".
  4. ^ "tulane.edu" (PDF).
  5. ^ Varma, Daya R.; Mulay, Shree (2009-01-01), Gupta, Ramesh C. (ed.), "CHAPTER 21 - Methyl Isocyanate: The Bhopal Gas", Handbook of Toxicology of Chemical Warfare Agents, San Diego: Academic Press, pp. 293–312, doi:10.1016/b978-0-12-374484-5.00021-3, ISBN 978-0-12-374484-5, retrieved 2024-04-02
  6. ^ "Pulmonary Eosinophilic Disorder Center | Tulane School of Medicine". medicine. Tulane.edu. Retrieved 2024-04-02.
  7. ^ Kandikattu, Hemanth Kumar; Upparahalli Venkateshaiah, Sathisha; Mishra, Anil (2019-06-01). "Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases". Cytokine & Growth Factor Reviews. 47: 83–98. doi:10.1016/j.cytogfr.2019.05.003. ISSN 1359-6101. PMC 6781864. PMID 31126874.
  8. ^ Kandikattu, Hemanth Kumar; Venkateshaiah, Sathisha Upparahalli; Kumar, Sandeep; Mishra, Anil (2020-08-01). "IL-15 immunotherapy is a viable strategy for COVID-19". Cytokine & Growth Factor Reviews. Therapeutic Opportunities in the Management of COVID-19. 54: 24–31. doi:10.1016/j.cytogfr.2020.06.008. ISSN 1359-6101. PMC 7537239. PMID 32536564.
[edit]